EUVIMEDEUVIMED entdecken
Crossref

Investigating Genetic Risk to Oxaliplatin-Induced Sinusoidal Obstruction Syndrome in Colorectal Cancer Through Routinely Available Next-Generation Sequencing Data

Mengxue Zhang, Peng Wang, Yang Kong, Daniela D Gaudio, Nick Parente, Ashley Hayden, Namrata Setia, John Hart

Modern Pathology · 2026-05 · 39 (5) · 100988

DOI: 10.1016/j.modpat.2026.100988 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Modern Pathology, 2026-05. Verfasst von Mengxue Zhang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, University of Chicago, Chicago, Illinois. Hauptthemen laut MEDLINE: Hepatic Veno-Occlusive Disease, Oxaliplatin, Colorectal Neoplasms, Antineoplastic Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 52 Literaturangaben. Gefördert von: University of Chicago, Department of Public Health Sciences, University of Rochester Medical Center.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Sinusoidal obstruction syndrome (SOS) is a known adverse effect of oxaliplatin, causing significant morbidity and cessation of chemotherapy. Recent studies suggest single nucleotide polymorphisms (SNPs) of certain genes may predispose carriers to oxaliplatin-induced liver toxicity. This study aims to evaluate candidate SOS-predisposing SNPs by correlating routinely available next-generation sequencing (NGS) data with clinical and histologic evidence of SOS. Seventy-nine colorectal cancer (CRC) cases with liver metastases and clinical NGS data were identified. A combination of clinical, biochemical, and histologic criteria was used to identify 12 cases with confirmed SOS. Additionally, 10 control cases were selected with no clinical or histological evidence of SOS. Clinical data and SOS-related findings were collected. For each patient, the expanded panel NGS data obtained for clinical management was reanalyzed to assess 12 polymorphisms in ERCC1, ERCC2, ABCB1, GSTP1, DPYD, MTHFR, ABCC2, UGT1A1, GSTT1, and GSTM1 known to be associated with oxaliplatin toxicity, as identified in the PharmGKB database. Statistical analyses, including Fisher's exact test and odds ratios were performed. The strongest nominal signal was observed in the prevalence of ERCC1 rs11615 (A>G) in SOS and control groups (allelic p-value=0.006, false discovery rate [FDR] q=0.072). The odds ratio for developing SOS associated with rs11615 (A>G) was 0.15 (95% confidence interval: 0.04-0.59), indicating a protective effect of the ERCC1 rs11615 (A>G). There was a noticeable numerical increase in ascites frequency, levels of aspartate aminotransferase (AST) and alanine aminotransferase (ALT), and frequency of neuropathy in the SOS group, albeit not statistically significant. These findings highlight the utility of expanded analysis of routinely obtained NGS panel results at the time of CRC diagnosis at many medical centers to personalize the chemotherapy regimen. Our data suggest that patients who carry the ERCC1 rs11615 (A>G) variant may be protected from developing oxaliplatin-induced SOS and those lacking the G allele should be monitored more carefully after oxaliplatin use.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hepatic Veno-Occlusive DiseaseOxaliplatinColorectal NeoplasmsAntineoplastic AgentsLiver NeoplasmsHumansPolymorphism, Single NucleotideHigh-Throughput Nucleotide SequencingGenetic Predisposition to DiseaseFemaleMaleMiddle AgedAgedAdultRisk FactorsAged, 80 and over

Stichwörter der Autor:innen

colorectal cancerhepatic sinusoidal obstruction syndromenext-generation sequencingpharmacogeneticssingle-nucleotide polymorphism

Substanzen

OxaliplatinAntineoplastic Agents

Autor:innen und Institutionen

  • Department of Pathology, University of Chicago, Chicago, Illinois.
  • Department of Human Genetics, University of Chicago, Chicago, Illinois.
  • Department of Pathology, University of Chicago, Chicago, Illinois. Electronic address: john.hart@bsd.uchicago.edu.

Förderung

  • University of Chicago
  • Department of Public Health Sciences, University of Rochester Medical Center

Zitieren

APA

Zhang, M., Wang, P., Kong, Y., Gaudio, D. D., Parente, N., Hayden, A., Setia, N., & Hart, J. (2026). Investigating Genetic Risk to Oxaliplatin-Induced Sinusoidal Obstruction Syndrome in Colorectal Cancer Through Routinely Available Next-Generation Sequencing Data. Modern Pathology, 39(5), 100988. https://doi.org/10.1016/j.modpat.2026.100988

Vancouver

Zhang M, Wang P, Kong Y, Gaudio DD, Parente N, Hayden A, et al. Investigating Genetic Risk to Oxaliplatin-Induced Sinusoidal Obstruction Syndrome in Colorectal Cancer Through Routinely Available Next-Generation Sequencing Data. Modern Pathology. 2026;39(5):100988. doi:10.1016/j.modpat.2026.100988

BibTeX
@article{Zhang2026,
  author = {Zhang, Mengxue and Wang, Peng and Kong, Yang and Gaudio, Daniela D and Parente, Nick and Hayden, Ashley and Setia, Namrata and Hart, John},
  title = {Investigating Genetic Risk to Oxaliplatin-Induced Sinusoidal Obstruction Syndrome in Colorectal Cancer Through Routinely Available Next-Generation Sequencing Data},
  journal = {Modern Pathology},
  year = {2026},
  volume = {39},
  number = {5},
  pages = {100988},
  doi = {10.1016/j.modpat.2026.100988}
}
Kostenlos starten →